Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Janus family of protein tyrosine kinase (Jak) inhibitor
cytokine
immune system
signal transduction
therapy
tyrosine kinase 2 (Tyk2)
Journal
Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
11
2
2022
Statut:
ppublish
Résumé
Tyrosine kinase 2 (Tyk2) is a member of the Janus family of protein tyrosine kinases (Jaks). Tyk2 associates with interferon (IFN)-α, IFN-β, interleukin (IL)-6, IL-10, IL-12, and IL-23 receptors and mediates their downstream signaling pathways. Based on our data using Tyk2-deficient mice and cells, Tyk2 plays crucial roles in the differentiation, maintenance, and function of T helper 1 (Th1) and Th17 cells, and its dysregulation may promote autoimmune and/or inflammatory diseases. IFN-α-induced growth inhibition of B lymphocyte progenitors is dependent on Tyk2-mediated signals to regulate death-associated protein (Daxx) nuclear localization and Daxx-promyelocytic leukemia protein interactions. Tyk2-deficient mice show impaired constitutive production of type I IFNs by macrophages under steady-state conditions. When heat-killed Cutibacterium acnes is injected intraperitoneally, Tyk2-deficient mice show less granuloma formation through enhanced prostaglandin E
Identifiants
pubmed: 34719635
doi: 10.1248/bpb.b21-00609
doi:
Substances chimiques
TYK2 Kinase
EC 2.7.10.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1585-1592Commentaires et corrections
Type : ErratumIn